These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2093285)

  • 1. [The ototoxicity of cisplatin: a clinical study].
    Vantrappen G; Rector E; Debruyne F
    Acta Otorhinolaryngol Belg; 1990; 44(4):415-21. PubMed ID: 2093285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-frequency testing techniques and instrumentation for early detection of ototoxicity.
    Fausti SA; Frey RH; Henry JA; Olson DJ; Schaffer HI
    J Rehabil Res Dev; 1993; 30(3):333-41. PubMed ID: 8126658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P; Fengler R; Hartmann R; Henze G
    Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cisplatin ototoxicity. A clinical study].
    Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
    Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
    Li Y; Womer RB; Silber JH
    Eur J Cancer; 2004 Nov; 40(16):2445-51. PubMed ID: 15519518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
    Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
    Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
    Kopelman J; Budnick AS; Sessions RB; Kramer MB; Wong GY
    Laryngoscope; 1988 Aug; 98(8 Pt 1):858-64. PubMed ID: 3398663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of high-tone audiometry in monitoring for ototoxicity.
    Tange RA; Dreschler WA; van der Hulst RJ
    Arch Otorhinolaryngol; 1985; 242(1):77-81. PubMed ID: 3899068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR; Kraemer DF; Winter C; Neuwelt EA
    J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
    Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
    Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ototoxicity of cisplatin in gynaecological cancer patients.
    Laurell G; Borg E
    Scand Audiol; 1988; 17(4):241-7. PubMed ID: 3232027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
    Riedemann L; Lanvers C; Deuster D; Peters U; Boos J; Jürgens H; am Zehnhoff-Dinnesen A
    Pharmacogenomics J; 2008 Feb; 8(1):23-8. PubMed ID: 17457342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ototoxic side effects in patients with ovarian cancer treated with cisplatin].
    Behling H; Spieske C; Krafft W
    Zentralbl Gynakol; 1988; 110(5):277-82. PubMed ID: 3376611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-based chemotherapy: Add high-frequency audiometry in the regimen.
    Arora R; Thakur JS; Azad RK; Mohindroo NK; Sharma DR; Seam RK
    Indian J Cancer; 2009; 46(4):311-7. PubMed ID: 19749461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
    Reddel RR; Kefford RF; Grant JM; Coates AS; Fox RM; Tattersall MH
    Cancer Treat Rep; 1982 Jan; 66(1):19-23. PubMed ID: 7198012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
    van der Hulst RJ; Dreschler WA; Urbanus NA
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of high-frequency audiometry in early detection of ototoxicity.
    Dreschler WA; vd Hulst RJ; Tange RA; Urbanus NA
    Audiology; 1985; 24(6):387-95. PubMed ID: 4084111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.